logo
Plus   Neg
Share
Email

Biogen, Sangamo Sign Deal To Develop Gene Therapies For Neurological Diseases

Biogen Inc. (BIIB) and Sangamo Therapeutics Inc. (SGMO), Thursday announced that they have reached a global collaboration deal to develop gene regulation therapies for Alzheimer's, Parkinson's, neuromuscular, and other neurological diseases.

The companies said that they will develop and commercialize ST-501 for tauopathies including Alzheimer's disease, ST-502 for synucleinopathies including Parkinson's disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets.

The companies will leverage Sangamo's proprietary zinc finger protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases.

"As a pioneer in neuroscience, Biogen will collaborate with Sangamo on a new gene regulation therapy approach, working at the DNA level, with the potential to treat challenging neurological diseases of global significance. We aim to develop and advance these programs forward to investigational new drug applications," said Alfred Sandrock Jr., M.D., Ph.D., Executive Vice President, Research and Development at Biogen.

SGMO closed Thursday's trading at $6.66, down $0.22 or 3.27%, on the Nasdaq. The stock, however, gained $2.60 or 38.93%, in the after-hours trade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Union and Britain have cleared Boeing's 737 Max for return to service in their respective regions after being grounded for nearly two years. The EU's air safety watchdog European Union Aviation Safety Agency or EASA in a statement said the agency has approved the return to service of a modified version of the Boeing 737 MAX. The UK Civil Aviation Authority or CAA also lifted the ban. Euromarket Designs, Inc., doing business as CB2, has recalled Junction tall chests and low dressers citing tip-over and entrapment hazards to children, according to the U.S. Consumer Product Safety Commission. The Chicago, Illinois - based company has called back about 11,000 units sold in the United States and about 355 units sold in Canada. Samsung Electronics Co Ltd (SMSN.L, SSNNF.OB, SSNLF.OB) reported a profit for the fourth-quarter that increased 23.3 percent from last year, led by display and memory chip businesses.Quarterly revenue grew 2.8 percent from the prior year. The company expects overall profit to weaken in the first quarter of 2021.
RELATED NEWS
Follow RTT